© 2019 Wundr Co.  London, Berlin, Toronto  info@wundrco.com

Wundr Co. Announces Acquisition of iuvo Therapeutics GmbH - Germany's Largest Independent Medical Cannabis Distributor

Coincides with iuvo's Receipt of TerrAscend's First Medical Cannabis Shipment to Germany

August 14, 2019 – London, UK - Wundr Co. (the "Company"), a European cannabis pioneer headquartered in London, is pleased to announce that it has acquired iuvo Therapeutics GmbH ("iuvo Therapeutics" or "iuvo"). iuvo Therapeutics is Germany's largest independent medical cannabis distributor, holding both medical cannabis import and narcotics distribution licenses for the EU. This acquisition establishes Wundr Co. as one of Europe's leading independent medical cannabis companies.

 

iuvo Therapeutics announced today that it has successfully imported the first international shipment of dry cannabis flower from TerrAscend, one of only six Canadian licensed producers with an EU Good Manufacturing Practices ("GMP") certified facility. TerrAscend and iuvo Therapeutics were recently granted an Export Permit by Health Canada under the Cannabis Act, and an Import Authorization from Germany's Federal Institute for Drugs and Medical Devices.

 

With an estimated 30,000 medical cannabis patients consuming more than 7,200 kg annually, Germany has quickly become one of Europe's largest cannabis markets and is expected to generate more than $5 billion in revenue by 2025. The iuvo-TerrAscend partnership presents a significant opportunity for Wundr Co. to generate meaningful revenues, fulfilling the growing needs of medical cannabis patients in Germany and the EU.

 

This acquisition provides Wundr Co. with a cornerstone medical cannabis asset soon to be augmented by additional M&A opportunities in the European market.

 

About Wundr Co.

Wundr Co. is a London-based cannabis company that is focused on helping European patients and consumers in the most precise and effective ways. Our diversified team features in depth knowledge and expertise across the cannabis supply chain.

 

About iuvo Therapeutics

iuvo Therapeutics GmbH was founded in 2017 and is a fully licensed GDP/GMP pharmaceutical wholesaler in Germany. The Company has the only independent license allowing them to both distribute and release medical cannabis products across the EU.

 

Advisors and Counsel

Beacon Securities Limited acted as Wundr Co.'s financial advisor, DLA Piper (Canada) LLP acted as Wundr Co.'s Canadian counsel, DLA Piper UK LLP acted as Wundr Co.'s German counsel, and Memery Crystal LLP acted as UK counsel in the transaction.

 

Contact

For general enquiries, please contact info@wundrco.com or visit www.wundrco.com.

 

Media enquiries

Jaime Hackett

jaime@wundrco.com // +1.647.223.7165

 

Advisory regarding forward-looking statements

 

This news release includes forward-looking information and forward-looking statements within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements") regarding Wundr Co. and its business. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. The forward-looking statements ‎contained in this press release speak only as of the date thereof ‎and are expressly qualified by this ‎cautionary statement. ‎

 

Specifically, this news release contains forward-looking statements relating to, but not limited to: ‎our business strategies, markets, plans and objectives‎. These forward-looking statements are based on certain key assumptions regarding, among other ‎things: our ability to execute on our business plan; revenue expectations; our operating activities; regulatory regimes; market growth and receptiveness; and current industry conditions, ‎laws and regulations continuing in effect (or, where changes are proposed, such changes being ‎adopted as anticipated). Readers are cautioned that such assumptions, although considered ‎reasonable by management at the time of preparation, may prove to be incorrect.‎

 

Actual results achieved will vary from the information provided herein as a result of numerous ‎known and unknown risks, uncertainties and other factors.‎

 

The above summary of assumptions and risks related to forward-looking statements in this news ‎release has been provided in order to provide shareholders and potential investors with a more ‎complete perspective on Wundr Co.'s current and future operations and such information may not ‎be appropriate for other purposes. There is no representation by Wundr Co. that actual results ‎achieved will be the same in whole or in part as those referenced in the forward-looking ‎statements and Wundr Co. does not undertake any obligation to update publicly or to revise any ‎of the included forward-looking statements, whether as a result of new information, future ‎events or otherwise, except as may be required by applicable securities law.‎